Cargando…
Biopsy of breast cancer metastases: patient characteristics and survival
BACKGROUND: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whet...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210262/ https://www.ncbi.nlm.nih.gov/pubmed/28052766 http://dx.doi.org/10.1186/s12885-016-3014-6 |
_version_ | 1782490848161693696 |
---|---|
author | Shachar, Shlomit Strulov Mashiach, Tanya Fried, Georgeta Drumea, Karen Shafran, Noa Muss, Hyman B. Bar-Sela, Gil |
author_facet | Shachar, Shlomit Strulov Mashiach, Tanya Fried, Georgeta Drumea, Karen Shafran, Noa Muss, Hyman B. Bar-Sela, Gil |
author_sort | Shachar, Shlomit Strulov |
collection | PubMed |
description | BACKGROUND: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. METHODS: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. RESULTS: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010–2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). CONCLUSIONS: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality. |
format | Online Article Text |
id | pubmed-5210262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52102622017-01-06 Biopsy of breast cancer metastases: patient characteristics and survival Shachar, Shlomit Strulov Mashiach, Tanya Fried, Georgeta Drumea, Karen Shafran, Noa Muss, Hyman B. Bar-Sela, Gil BMC Cancer Research Article BACKGROUND: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. METHODS: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. RESULTS: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010–2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). CONCLUSIONS: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality. BioMed Central 2017-01-04 /pmc/articles/PMC5210262/ /pubmed/28052766 http://dx.doi.org/10.1186/s12885-016-3014-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Shachar, Shlomit Strulov Mashiach, Tanya Fried, Georgeta Drumea, Karen Shafran, Noa Muss, Hyman B. Bar-Sela, Gil Biopsy of breast cancer metastases: patient characteristics and survival |
title | Biopsy of breast cancer metastases: patient characteristics and survival |
title_full | Biopsy of breast cancer metastases: patient characteristics and survival |
title_fullStr | Biopsy of breast cancer metastases: patient characteristics and survival |
title_full_unstemmed | Biopsy of breast cancer metastases: patient characteristics and survival |
title_short | Biopsy of breast cancer metastases: patient characteristics and survival |
title_sort | biopsy of breast cancer metastases: patient characteristics and survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210262/ https://www.ncbi.nlm.nih.gov/pubmed/28052766 http://dx.doi.org/10.1186/s12885-016-3014-6 |
work_keys_str_mv | AT shacharshlomitstrulov biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT mashiachtanya biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT friedgeorgeta biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT drumeakaren biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT shafrannoa biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT musshymanb biopsyofbreastcancermetastasespatientcharacteristicsandsurvival AT barselagil biopsyofbreastcancermetastasespatientcharacteristicsandsurvival |